Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Fallopian tube cancer

Fallopian tube cancer

Part of Adnexal Diseases

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Fallopian tube cancer

93 trials tracked for Fallopian tube cancer: 13 in phase 3 or 4 and 7 with published results. The most-cited published study has 438 citations.

93Trials tracked
13Phase 3 & 4
0Recruiting
7With published results
Phase distribution
Phase 3 13 Phase 2 65 Phase 1 11 Other / NA 4
  1. Phase 3 A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression Completed · 438 cited
  2. Phase 3 A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed · 410 cited
  3. Phase 3 A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Completed · 375 cited
  4. Phase 3 A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer Completed · 295 cited
  5. Phase 3 ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Completed · 143 cited
  6. Phase 3 Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) Completed · 130 cited
Show 44 more trials
  1. Phase 3 A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed · 18 cited
  2. Phase 3 Accelerating Gastrointestinal Recovery Completed
  3. Phase 3 CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib Completed
  4. Phase 3 Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) Completed
  5. Phase 3 Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer Completed
  6. Phase 3 Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed
  7. Phase 3 Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer Completed
  8. Phase 2 Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer Completed
  9. Phase 2 A Study LY2228820 for Recurrent Ovarian Cancer Completed
  10. Phase 2 Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer Completed
  11. Phase 2 Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed
  12. Phase 2 A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208) Completed
  13. Phase 2 Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Completed
  14. Phase 2 Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Completed
  15. Phase 2 European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer Completed
  16. Phase 2 Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer Completed
  17. Phase 2 A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) Completed
  18. Phase 2 A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Completed
  19. Phase 2 Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers Completed
  20. Phase 2 Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Completed
  21. Phase 2 Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed
  22. Phase 2 Study of Ramucirumab in Ovarian Cancer Completed
  23. Phase 2 AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer Completed
  24. Phase 2 Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Completed
  25. Phase 2 S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed
  26. Phase 2 Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer Completed
  27. Phase 2 Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies Completed
  28. Phase 2 Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer Completed
  29. Phase 2 A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers Completed
  30. Phase 2 Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer Completed
  31. Phase 2 Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer Completed
  32. Phase 2 A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) Completed
  33. Phase 2 Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy Completed
  34. Phase 2 Irinotecan and Bevacizumab for Recurrent Ovarian Cancer Completed
  35. Phase 2 Neoadjuvant Therapy for Ovarian Cancer Completed
  36. Phase 2 Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed
  37. Phase 2 Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab Completed
  38. Phase 2 Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer Completed
  39. Phase 2 Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers Completed
  40. Phase 2 A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment Completed
  41. Phase 2 Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Completed
  42. Phase 2 Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer Completed
  43. Phase 2 Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer Completed
  44. Phase 2 Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer Completed

Showing the 50 most-cited and recently-updated of 93 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Fallopian tube cancer: what the trials found

New clinical evidence highlights the efficacy of several targeted and systemic therapies. Pembrolizumab demonstrated a 95% progression-free survival (PFS) rate at 6 months when following pre-trial weekly Paclitaxel 1, while also showing significant improvement in PFS for patients with PD-L1 positive tumors compared to other cohorts 12. Rucaparib showed superior investigator-assessed progression-free survival (invPFS) and duration of response (DOR) compared to chemotherapy [9, 10].

Mirvetuximab soravtansine demonstrated significant clinical activity across multiple trials. It achieved high CA-125 confirmed clinical response rates in various cohorts [2, 6, 7, 8] and showed statistically significant improvements in progression-free survival compared to other regimens 6. Additionally, Mirvetuximab soravtansine was associated with varying objective response rates (ORR) across different dose expansion and escalation protocols 20.

Paclitaxel remains a standard of care; however, results varied across studies. One trial showed no significant difference in 6-month PFS or overall survival between Paclitaxel arms 15, while another demonstrated significantly improved progression-free survival in one specific cohort compared to others 11.

Recent results — preliminary, needs further review

  • Pegylated Liposomal Doxorubicin + SL-172154 is currently under investigation in a Phase 1 trial 3.

For the clinician treating this condition

  • Rucaparib has demonstrated superior progression-free survival and duration of response compared to chemotherapy [9, 10].
  • Mirvetuximab soravtansine shows consistent clinical activity with significant improvements in progression-free survival and high CA-125 response rates across multiple studies [6, 7, 8].
  • Pembrolizumab showed a 95% 6-month PFS rate following pre-trial Paclitaxel and demonstrated efficacy in PD-L1 positive populations [1, 12].

AI synthesis of 7 cited trials, updated Jun 21, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Narrative review on precision prevention for women with inherited gynecologic cancer susceptibility
Oncology Sys. Review
Narrative review on precision prevention for women with inherited gynecologic cancer susceptibility New Plan Cuts Cancer Risk for High-Risk Women
This narrative review addresses ovarian, endometrial, and fallopian tube cancer in women with inherited gynecologic cancer susceptibility.
Women with strong family histories of ovarian or uterine cancer can now take smarter, personalized steps to reduce their risk — and it’s cha…
Frontiers Apr 28, 2026